Search results
Results From The WOW.Com Content Network
Peginterferon beta-1a, sold under the brand name Plegridy, is medication used to treat multiple sclerosis. [4] [5]The most common side effects include headache, muscle pain, joint pain, influenza (flu)-like symptoms, pyrexia (fever), chills, asthenia (weakness), and erythema (reddening of the skin), pain or pruritus (itching) at the injection site.
Pegylated interferon alfa-2a, sold under the brand name Pegasys among others, is medication used to treat hepatitis C and hepatitis B. [3] For hepatitis C it is typically used together with ribavirin and cure rates are between 24 and 92%. [3] [4] For hepatitis B it may be used alone. [5] It is given by injection under the skin. [3] Side effects ...
Pegylated interferon alfa-2b is a drug used to treat melanoma, as an adjuvant therapy to surgery. [3] Also used to treat hepatitis C (typically, in combination with ribavarin), it is no longer recommended due to poor efficacy and adverse side-effects. [4] Subcutaneous injection is the preferred delivery method. [3]
Peginterferon-alfa may refer to: Peginterferon alfa-2a, an antiviral drug used in treatment for hepatitis C and hepatitis B; Peginterferon alfa-2b, a treatment for ...
This page was last edited on 26 June 2016, at 20:17 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may ...
Interferon beta-1a (also interferon beta 1-alpha) is a cytokine in the interferon family used to treat multiple sclerosis (MS). [5] It is produced by mammalian cells, while interferon beta-1b is produced in modified E. coli. [6] Some research indicates that interferon injections may result in an 18–38% reduction in the rate of MS relapses. [7]
When used with the antiviral drug ribavirin, PEGylated interferon is effective in treatment of hepatitis C; at least 75% of people with hepatitis C genotypes 2 or 3 benefit from interferon treatment, although this is effective in less than 50% of people infected with genotype 1 (the more common form of hepatitis C virus in both the U.S. and ...
It was approved for medical use in the European Union in February 2019, [4] and in the United States in November 2021. [ 3 ] [ 6 ] Ropeginterferon alfa-2b is the first medication approved by the US Food and Drug Administration (FDA) to treat polycythemia vera that people can take regardless of their treatment history, and the first interferon ...